1-20 of 58
Geoffrey I. Shapiro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Gregory M. Cote, Bose S. Kochupurakkal, Khanh Do, Andrea Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, Xin Gao, Aparna Parikh, Jong Chul Park, Colin D. Weekes, Oladapo Yeku, Lee Zou, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 35–44.
https://doi.org/10.1158/1078-0432.CCR-24-1867
Published: 06 January 2025
View article titled, A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Open the PDF for A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Cristina Guarducci, Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Heraud, Albert Grinshpun, Qi Zhang, Allegra Freelander, Mathew Joseph Leventhal, Avery Feit, Gabriella Cohen Feit, Ariel Feiglin, Weihan Liu, Francisco Hermida-Prado, Nikolas Kesten, Wen Ma, Carmine De Angelis, Antonio Morlando, Madison O'Donnell, Sergey Naumenko, Shixia Huang, Quang-Dé Nguyen, Ying Huang, Luca Malorni, Johann S. Bergholz, Jean J. Zhao, Ernest Fraenkel, Elgene Lim, Rachel Schiff, Geoffrey I. Shapiro, Rinath Jeselsohn
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1889–1905.
https://doi.org/10.1158/1078-0432.CCR-23-2975
Published: 01 May 2024
View article titled, Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
Open the PDF for Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran, Khanh T. Do, Jeong E. Kim, James M. Cleary, Aparna R. Parikh, Oladapo O. Yeku, Niya Xiong, Colin D. Weekes, Jennifer Veneris, Leanne G. Ahronian, Gianluca Mauri, Jun Tian, Bryanna L. Norden, Alexa G. Michel, Emily E. Van Seventer, Giulia Siravegna, Kyle Camphausen, Gary Chi, Isobel J. Fetter, Joan S. Brugge, Helen Chen, Naoko Takebe, Richard T. Penson, Dejan Juric, Keith T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, Ursula A. Matulonis, Joyce F. Liu, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1739–1749.
https://doi.org/10.1158/1078-0432.CCR-23-3135
Published: 01 May 2024
View article titled, Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Open the PDF for Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Brandon M. Huffman, Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S. Kapner, Bose Kochupurakkal, David B. Martignetti, Golbahar Sadatrezaei, Thomas A. Abrams, Leah H. Biller, Marios Giannakis, Kimmie Ng, Anuj K. Patel, Kimberly J. Perez, Harshabad Singh, Douglas A. Rubinson, Benjamin L. Schlechter, Elizabeth Andrews, Alison M. Hannigan, Stanley Dunwell, Zoe Getchell, Srivatsan Raghavan, Brian M. Wolpin, Caroline Fortier, Alan D. D'Andrea, Andrew J. Aguirre, Geoffrey I. Shapiro, James M. Cleary
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5047–5056.
https://doi.org/10.1158/1078-0432.CCR-23-2005
Published: 15 December 2023
View article titled, A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Open the PDF for A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer

Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan, Elizabeth F. Cohen, Michael Tolstorukov, Elizabeth Andrews, Lauren K. Brais, Annacarolina da Silva, Kimberly Perez, Douglas A. Rubinson, Rishi Surana, Marios Giannakis, Kimmie Ng, Thomas E. Clancy, Matthew B. Yurgelun, Benjamin L. Schlechter, Jeffrey W. Clark, Geoffrey I. Shapiro, Michael H. Rosenthal, Jason L. Hornick, Valentina Nardi, Yvonne Y. Li, Hersh Gupta, Andrew D. Cherniack, Matthew Meyerson, James M. Cleary, Jonathan A. Nowak, Brian M. Wolpin, Andrew J. Aguirre
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4627–4643.
https://doi.org/10.1158/1078-0432.CCR-22-3930
Published: 14 November 2023
View article titled, Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Open the PDF for Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti, Arielle Elkrief, Joao Alessi, Xinan Wang, Yvonne Li, Hersh Gupta, Daniel M. Muldoon, Arrien A. Bertram, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Adriana Barrichello, Victor R. Vaz, Malini Gandhi, Elinton Lee, Geoffrey I. Shapiro, Hyesun Park, Mizuki Nishino, James Lindsay, Kristen D. Felt, Bijaya Sharma, Andrew D. Cherniack, Scott Rodig, Daniel R. Gomez, Narek Shaverdian, Mehrdad Rakaee, Chaitanya Bandlamudi, Marc Ladanyi, Pasi A. Janne, Adam J. Schoenfeld, Lynette M. Sholl, Mark M. Awad, Michael L. Cheng
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2540–2550.
https://doi.org/10.1158/1078-0432.CCR-22-3413
Published: 05 July 2023
View article titled, Clinicopathologic, Genomic, and Immunophenotypic Landscape of <em>ATM</em> Mutations in Non–Small Cell Lung Cancer
Open the PDF for Clinicopathologic, Genomic, and Immunophenotypic Landscape of <em>ATM</em> Mutations in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean-Pierre Delord, Ahmad Awada, Pascaline Boudou-Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernandez, Carmen Kahatt, Martin Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2762–2770.
https://doi.org/10.1158/1078-0432.CCR-22-0696
Published: 01 July 2022
View article titled, Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Open the PDF for Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study in another window
Journal Articles

Report of the First International Symposium on NUT Carcinoma

Christopher A. French, Michael L. Cheng, Glenn J. Hanna, Steven G. DuBois, Nicole G. Chau, Christine L. Hann, Simone Storck, Ravi Salgia, Matteo Trucco, Jennifer Tseng, Anastasios Stathis, Richard Piekarz, Ulrich M. Lauer, Christophe Massard, Kelly Bennett, Shodeinde Coker, Ulrike Tontsch-Grunt, Martin L. Sos, Sida Liao, Catherine J. Wu, Kornelia Polyak, Sarina A. Piha-Paul, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2493–2505.
https://doi.org/10.1158/1078-0432.CCR-22-0591
Published: 13 June 2022
View article titled, Report of the First International Symposium on NUT Carcinoma
Open the PDF for Report of the First International Symposium on NUT Carcinoma in another window
Journal Articles

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela-Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2257–2269.
https://doi.org/10.1158/1078-0432.CCR-21-3087
Published: 01 June 2022
View article titled, A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1493–1499.
https://doi.org/10.1158/1078-0432.CCR-21-3045
Published: 14 April 2022
View article titled, Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Open the PDF for Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View article titled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 298–307.
https://doi.org/10.1158/1078-0432.CCR-21-2007
Published: 15 January 2022
View article titled, Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Open the PDF for Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT in another window
Includes: Supplementary data
Journal Articles

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma

James M. Cleary, Brian M. Wolpin, Stephanie K. Dougan, Srivatsan Raghavan, Harshabad Singh, Brandon Huffman, Nilay S. Sethi, Jonathan A. Nowak, Geoffrey I. Shapiro, Andrew J. Aguirre, Alan D. D'Andrea
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6622–6637.
https://doi.org/10.1158/1078-0432.CCR-21-1367
Published: 15 December 2021
View article titled, Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
Open the PDF for Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma in another window
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View article titled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em>
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em> in another window
Includes: Supplementary data
Journal Articles

Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors

Khanh T. Do, Bose Kochupurakkal, Sarah Kelland, Adrienne de Jonge, Jennifer Hedglin, Allison Powers, Nicholas Quinn, Courtney Gannon, Loan Vuong, Kalindi Parmar, Jean-Bernard Lazaro, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4710–4716.
https://doi.org/10.1158/1078-0432.CCR-21-1279
Published: 01 September 2021
View article titled, Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Open the PDF for Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3845–3853.
https://doi.org/10.1158/1078-0432.CCR-20-4548
Published: 15 July 2021
View article titled, Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Open the PDF for Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations in another window
Includes: Supplementary data
Journal Articles

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Harshabad Singh, Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma Reilly, Lauren K. Brais, Anwesha Nag, Matthew D. Ducar, Aaron R. Thorner, Geoffrey I. Shapiro, Rachel B. Keller, Cheta Siletti, Jeffrey W. Clark, Anna F. Farago, Jessica J. Lin, George D. Demetri, Rahul Gujrathi, Matthew H. Kulke, Laura E. MacConaill, Azra H. Ligon, Ewa Sicinska, Matthew L. Meyerson, Jeffrey A. Meyerhardt, Andrew D. Cherniack, Brian M. Wolpin, Kimmie Ng, Marios Giannakis, Jason L. Hornick, James M. Cleary
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1695–1705.
https://doi.org/10.1158/1078-0432.CCR-20-4073
Published: 15 March 2021
View article titled, Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Open the PDF for Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie L. Lau, Lynette Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1604–1611.
https://doi.org/10.1158/1078-0432.CCR-20-4084
Published: 15 March 2021
View article titled, Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903)
Open the PDF for Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903) in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Tanya E. Keenan, Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae Davis, Ricardo Pastorello, Rie K. Tahara, Leilani Anderson, Jake Conway, Meng X. He, Erin Shannon, Robert E. Godin, Peter K. Sorger, Alan D'Andrea, Beth Overmoyer, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Geoffrey I. Shapiro, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 983–991.
https://doi.org/10.1158/1078-0432.CCR-20-3089
Published: 15 February 2021
View article titled, Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Open the PDF for Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data